References
- Scitovsky AA. Estimating the direct cost of illness. Mil 11/lem. Fund Quart 60,463–491 (1982).
- Hodgson TA. The state of the art of cost- of-illness estimates. Advances Health Econ. Health Serv Res. 4,129–164 (1983).
- Rice D. Cost-of-illness studies: fact or fiction? Lancet 344, 1519–1520 (1994).
- Mauskopf J. Why study pharmacoeconomics? Expert Rev Pharmacoeconomics Outcomes Res. 1(1), 1–3 (2001).
- Rice DP, Cooper BS. The Economic value of human life. Am J. Pub. Health 57, 1954–1966 (1967).
- Mishan EJ. Cost-benefit analysis. 4th ed. Unwin Hyman, Boston, MA, USA (1988).
- Jacobs P. Cost-benefit analysis. In: The Economics of Health and Medical Cam, 2nd ed. Aspen Publications, Rockville, MD, USA (1987).
- Schelling TC. The life you save may be your own. In: Problems in Public Expenditure Analysis. Chase SB (Ed.), Brookings Institution, Washington DC, USA (1968).
- Lilienfeld D, Stolley P. Foundations of Epidemiology 31r1 ed. Oxford University Press, New York, NY, USA (1994).
- Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin.Therapeut. 20(6), 1194–1202 (1998).
- Hodgson TA, Meiner MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank .11/km. Fund Q Health Soc. 60(3), 429–462 (1982).
- Rice DR Estimating the cost &illness. Health Economics Series, 6. DHEW (PHS)947-6. US Department of Health, Education and Welfare, Rockville, MD, USA (1966).
- Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Healthcare Fin. Rev7 (1), 61–80 (1985).
- Cruze AM, Harwood HJ, Kristiansen PC et al Economic costs to society of alcohol and drug abuse and mental illness, Research Triangle Institute, Research Triangle Park, NC, USA (1981).
- Harwood HJ, Napolitano DM, Kristiansen P, Collins JJ. Economic Costs to Society of Alcohol and Drug Abuse and Mental illness, Research Triangle Institute, Research Triangle Park, NC, USA (1984).
- Hodgson TA. Annual costs of illness versus lifetime costs of illness and implications of structural change. Drug Info.1. 22, 323–341 (1988).
- Hodgson TA, Meiners M. Guidelines for Cost of illness Studies in the Public Health Service. Task Force on Cost of Illness Studies, US Public Health Service, Washington, DC, USA (1979).
- Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease and stroke: a comparative analysis. Am. j Pub. Health. 70, 1249–1260 (1980).
- Evaluation of cost-of-illness ascertainment methodology. Part 1: Concepts, issues and methodology of cost-of-illness ascertainment. Policy Analysis Inc., MI, USA. Final Report to the National Center for Health Statistics. DHHS Contract No. 233-79-2048 (Unpublished) (1981).
- Berry RE, Boland JR The Economic Cost of Alcohol Abuse. Free Press, New York, NY, USA (1977).
- Luce BR. The implications of cost- effectiveness analysis of medical technology. Case study #7: allocating costs and benefits in disease prevention programs: an application to cervical cancer screening. Office of Technology Assessment, US Congress, USA (1981).
- Fuchs V. Who Shall Live? Health, Economics and Social Choke. Basic Books, New York, NY, USA (1974).
- McKeown T A historical appraisal of the medical task. In: Medical History and Medical Care. McLachlan G, McKeowen T (Eds), Oxford University Press, London, UK (1971).
- Dubos R. Man, Medicine and Environment Praeger, New York, NY, USA (1968).
- Mich I. Medical Nemesis, The Expropriation of Health. Pantheon Books, New York, NY, USA (1976).
- Birnbaum H. The Cost of Catastrophic illness, Lexington Books, Lexington, MA, USA (1978).
- Rice DP, McKenzie EJ. Cost of Injury in the US: a Report to Congress. School of Hygiene and Public Health, The Johns Hopkins University, MD, USA (1989).
- Anderson WD, Gunn SA. Cancer of the cervix: time interval in repeating a cytology smear. Can.j Clin. 17, 150 (1967).
- Walton RJ. Cervical cancer screening program. Can. Med A.j 114, 1003 (1976).
- Knox A. A simulation system for screening procedures: computer simulations of cervical cytology screening programmes. In: Problems and Progress in Medical Care. McLachlan EG (Ed.) Oxford University Press, London, UK (1973).
- Galliher HP. Optimal ages for pap smear using a multistrain model of cervical cancer. (Unpublished Manuscript). Michigan Cancer Foundation, Detroit, MI, USA (1977).
- Dickenson LE. Control of cancer of the uterine cervix by cytology screening. Gyn. Onc 3(1), 1 (1975).
- Schneider J, Twiggs L. The costs of carcinoma of the cervix. Obstet. Gyn. 40(6), 851 (1972).
- Department of Health, Education and Welfare, Disease Control Programs: Cancer DHEW publication No. 1966–3, US Government Printing Office, Washington, DC, USA (1966).
- Shaya FT, Mullins CD, Wong W. Incidence or prevalence: implications for formulary decision-making. Proceedings of the Seventh Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Researrh. Crystal City, VA, USA, May 19–22 (2002).
- Gricar J, Langley P, Lyles A et al A format for submission of clinical and economic evaluation data in support of formulary consideration by managed healthcare systems in the United States. Academy Managed C.7.1r P1111771. (2000) .
- Andrade SE, Gurwitz JH. Pharmacoepidemiology and the elderly. In: Drugs and the older population. Crome P, Ford G (Eds), Imperial College Press, London, UK, Distributed by World Scientific Publishing Co: River Edge, NJ, USA (2000).
- Scitovsky AA. Estimating the direct cost of illness. Mil A/rem. Fund Quart. 60, 463–491 (1982).
- Hodgson TA. The state of the art of cost- of-illness estimates. Advances Health Econ. Health Serv. Res. 4, 129–164 (1983).